KIR3DL2 Antibody

1. We show that KIR3DL2 expression is the most sensitive diagnostic criterion of Sezary syndrome when compared with all other available biological criteria. KIR3DL2 therefore represents a valuable tool for routine use as a clinical parameter at diagnosis, for prognosis and during patient follow-up PMID: 28119365
2. results identified significant KIR3DL2 expression in all cutaneous T-cell lymphomas subtypes PMID: 29089310
3. Overexpression of a single MHCI molecule, HLA-F, protects human MNs from ALS astrocyte-mediated toxicity, whereas knockdown of its receptor, the killer cell immunoglobulin-like receptor KIR3DL2, on human astrocytes results in enhanced motor neurons death PMID: 26928464
4. KIR-3DL2 binding to HLA-B27 licenses Th17 cell differentiation in spondyloarthritis. PMID: 26841353
5. In early axial spondyloarthritis and ankylosing spondylitis Dutch patients, no copy number changes were found for KIR3DL2. PMID: 25940819
6. we show that the allele KIR3DL2*001 and the single nucleotide polymorphism 1190T (rs3745902) are associated with differential susceptibility to pemphigus PMID: 25867094
7. CD158k expression was identified on cutaneous CD4+ T cells in healthy individuals and also mycosis fungoides patients. PMID: 25044837
8. These findings provide novel insights about the molecular basis of KIR3DL2 binding to B27 PMID: 25582852
9. these data provide evidence for a possible role of KIR3DL2 in the maintenance of a high circulating malignant-cell burden by preventing activation-induced cell death. PMID: 25414436
10. Our results indicate that KIR3DL2 can directly promote Sezary syndrome malignant cell death through the use of CpG ODN. PMID: 25007046
11. our results show that a multistep gating of CD158k+ cells is reliable to assess tumor burden in case of Sezary syndrome. PMID: 25158034
12. our results offer preclinical proof of concept for the clinical development of IPH4102, a humanized monoclonal antibody that targets the immune receptor KIR3DL2,to treat patients with nced cutaneous T-cell lymphoma PMID: 25361998
13. KIR3DL2 binds to HLA-B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis. PMID: 23440420
14. PLS3, Twist, KIR3DL2 and NKp46 gene expression can model efficient molecular Sezary syndrome diagnosis. PMID: 23429988
15. most frequently expressed KIR receptor in transformed mycosis fungoides PMID: 22621189
16. results suggest that carriers of A allele in exon 3 of killer cell immunoglobulin-like receptor 3DL2(KIR3DL2) have a decreased susceptibility to preeclampsia PMID: 21406041
17. Enhanced proliferation, survival, and interleukin (IL)-17 production of KIR3DL2+ CD4 T cells stimulated with antigen-presenting cells expressing HLA-B27 homodimers suggest new therapeutic strategies in ankylosing spondylitis. PMID: 21248258
18. Data show direct binding of KIR3DL2 to ODNs and we show that the D0 domain is involved primarily in this interaction. PMID: 20147700
19. The A52G polymorphism in exon 3 and the frequencies of C32T in exon 9 of KIR3DL2 gene polymorphism are associated with the pathogenesis of pre-eclampsia. PMID: 19953898
20. All genotypes seen included genes for KIR3DL2. PMID: 12559621
21. IR3DL2/p140 engagement does not result into inhibitory (nor activatory) effects on tumor-specific cytotoxic T lymphocytes. PMID: 14562047
22. A high level of KIR3DL2 allelic polymorphism has been identified. PMID: 15304002
23. Receptor is a marker for the diagnosis of Sezary syndrome. PMID: 16962036
24. Five new alleles are reported, and four previously known ones are confirmed. PMID: 17661911
25. observation that CD4 positive, CD7 negative T-cells are mostly CD158k negative suggests that CD158k may be able to help identify and enumerate neoplastic T-cells in Sezary syndrome PMID: 18061949
26. Functional analysis of KIR3DL2-single positive natural killer (NK) cells reveals a subset that is hyporesponsive in individuals harboring cognate ligands HLA-A3/A11. PMID: 18941190
27. Anti-p140 autoantibodies represent a major autoantibody subset in juvenile dermatomyositis. PMID: 19479859
28. Using shotgun mass spectrometry, we found this protein differentially expressed in the dorsolateral prefrontal cortex from patients with schizophrenia. PMID: 19165527

Show More

Hide All

HGNC: 6339

OMIM: 604947

KEGG: hsa:3812

STRING: 9606.ENSP00000325525

UniGene: Hs.645228